Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the Serum by Cossu, Marta et al.
Earliest Phase of Systemic Sclerosis Typified by Increased Levels
of Inflammatory Proteins in the Serum
Marta Cossu,1 Lenny van Bon,1 Carlo Preti,2 Marzia Rossato,1 Lorenzo Beretta,2
and Timothy R. D. J. Radstake1
Objective. Patients with definite systemic sclero-
sis (SSc) who lack fibrotic features can be stratified
into an intermediate stage of disease severity between
preclinical/early SSc (EaSSc) and fibrotic subsets (lim-
ited cutaneous SSc [lcSSc] and diffuse cutaneous SSc
[dcSSc]). The aim of the present study was to molecu-
larly characterize nonfibrotic SSc and EaSSc on the
basis of a broad panel of serum markers of inflamma-
tion and tissue damage, in order to increase the knowl-
edge of the pathophysiologic mechanisms underlying
SSc progression before the development of fibrosis.
Methods. An 88-plex immunoassay was per-
formed in serum samples from a discovery cohort com-
posed of 21 patients with EaSSc (meeting the LeRoy
and Medsger criteria), 15 with nonfibrotic SSc (meet-
ing the American College of Rheumatology/European
League Against Rheumatism 2013 classification crite-
ria, without skin or lung fibrosis), and 11 healthy con-
trols. Analyte concentrations that were consistently
significantly different at the exploratory P value
threshold of 0.1 were selected for replication analysis
in a larger group composed of 47 patients with EaSSc,
48 with nonfibrotic SSc, and 43 healthy controls, as
well as 51 patients with lcSSc and 35 with dcSSc. The
value of the replicated molecules in predicting SSc
progression (at a family-wise error rate of 0.05) was
tested.
Results. Based on the results of the explorative
analysis, 16 molecules were selected for testing in the
replication set. The results showed that CXCL10,
CXCL11, tumor necrosis factor receptor type II
(TNFRII), and chitinase 3–like protein 1 levels were
significantly increased in patients with EaSSc and
those with nonfibrotic SSc as compared to healthy con-
trols. The disease in patients with high concentrations
of CXCL10 and TNFRII was also characterized by a
faster rate of progression from EaSSc and from nonfi-
brotic SSc to worse disease stages.
Conclusion. SSc patients with preclinical/early
SSc and those with established, yet nonfibrotic, disease
exhibit clear molecular alterations that are associated
with faster rates of disease evolution. These data open
novel avenues for disease interception in SSc.
The hallmark of systemic sclerosis (SSc) consists
of fibrosis involving the skin and internal organs, with
pathologic development in the context of endothelial
damage and immune system activation. The sequence of
events leading to widespread collagen deposition in SSc
is largely unknown, but microvascular injury and perivas-
cular infiltration by mononuclear cells in genetically pre-
disposed individuals are considered early events in the
disease course (1,2). Raynaud’s phenomenon (RP) is
usually the first manifestation of the disease that may
antedate by years the onset of definite SSc. The pres-
ence of RP, SSc-specific autoantibodies, and SSc-specific
nailfold videocapillaroscopic (NVC) changes, even in
the absence of any other sign of definite SSc, identifies
individuals at higher risk of developing SSc, a subset
referred to as those with early SSc (EaSSc) (3) or those
with undifferentiated connective tissue disease at risk
for SSc (4).
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For years, the occurrence of skin fibrosis has
been considered the pivotal sign for identification and
classification of patients with SSc (5). However, it has
been widely recognized that a classification that relies
so extensively on the presence of skin fibrosis lacks
enough sensitivity to identify patients with limited or
early disease (6). The American College of Rheumatol-
ogy (ACR)/European League Against Rheumatism
(EULAR) 2013 classification criteria for SSc (6) were
specifically designed to circumvent this problem, and
fibrotic features are no longer a prerequisite to formal-
ize the diagnosis of SSc. The ACR/EULAR 2013 crite-
ria thus allow the identification of SSc even in the
absence of overt fibrosis. A consensus to properly
define this patient subset—a subset formerly termed as
“definite” SSc (7) or “noncutaneous” SSc (8)—does
not yet exist, and it is doubtful whether this designation
would represent a necessary intermediate phase of the
disease between EaSSc and fibrotic SSc or whether
such patients might cluster in a separate disease subset
characterized by a smoldering, slowly progressing
entity. From a clinical point of view, patients with non-
fibrotic SSc could be stratified in an intermediate stage
of disease severity between EaSSc (the least severe)
and the fibrotic subsets of SSc (the most severe) (7).
This peculiar intermediate pathologic behavior
can also be observed when a number of laboratory
parameters are taken into account, including indices of
inflammation or serum concentrations of circulating
markers of vascular activation and dysfunction (7).
Despite the existing evidence, a thorough molecular char-
acterization of these patients and individuals with EaSSc
is lacking. An increased knowledge about the biologic
characteristics of these subsets and about the changes
that occur early during evolution of the disease is indeed
of paramount importance to understand the pathophysio-
logic mechanisms of SSc progression. Moreover, this
increased knowledge would allow us to distinguish those
patients whose disease is bound to progress from those
whose disease will not progress and who will continue to
express a milder clinical phenotype, thus paving the way
for early intervention and/or disease interception.
Fueled by these considerations, we screened a
broad panel of serum markers of inflammation, tissue
damage, vascular dysfunction, metabolism, and remod-
eling in subsets of patients with definite SSc and those
with EaSSc in comparison to healthy controls. With a
2-step research strategy, we first identified a number of
analytes that were differently expressed in a discovery
cohort of patients with EaSSc and those with definite
SSc, and then replicated the results in a second, larger
cohort. We next assessed the validated molecules for
comparison to that in SSc patients with overt fibrosis.
Finally, to define the prospective value of these mole-
cules, we characterized the disease progression rates
retrospectively in each subset of SSc patients in the
replication cohort. To this end, the survival estimates
for patients with high or low levels of the validated
molecules were compared.
PATIENTS AND METHODS
Patients and healthy controls. Two different cohorts
of patients were considered for the study and identified using
a 2-step research design, with discovery and replication steps.
All patients were recruited in Italy, at the Scleroderma Unit
of the Fondazione IRCCS Ca’ Granda Policlinico di Milano.
For the discovery step, 21 patients with EaSSc (3) and
15 patients with SSc who met the ACR/EULAR 2013 classifi-
cation criteria (6) and who were without skin fibrosis (having a
modified Rodnan skin thickness score of 0 on a scale of 0–3,
where 3 indicates severe thickening [9]) and without any sign of
interstitial lung disease (ILD) or pulmonary arterial hyperten-
sion (PAH) (nonfibrotic SSc) were enrolled. ILD was defined
as a typical involvement of the lung parenchyma of >5% on
high-resolution computed tomography (10) accompanied by
reduction in the forced vital capacity (FVC) or diffusing capac-
ity for carbon monoxide (DLCO) of <80% of predicted, as pre-
viously described (11). In accordance with standardized
protocols, the presence of PAH is routinely screened in patients
with EaSSc and those with SSc, and is confirmed by right-sided
heart catheterization (12). None of the patients in the discovery
cohort were suspected of having PAH. The presence of puffy
fingers was ascertained by the referring physician and then
independently verified, in a blinded manner, by one of the
authors (LB), to correctly differentiate puffy fingers from scle-
rodactyly. When the 2 independent assessors were not in agree-
ment, consensus was reached. The duration of disease was
defined as the time from the occurrence of the first non-RP
symptom. The NVC pattern was assessed by an experienced
observer in our center and classified according to the criteria of
Cutolo et al (13). Eleven healthy control subjects, matched to
the patients by sex and age, were also included as a comparison
group in the discovery step.
For the replication step, sera from 224 subjects, whose
characteristics have previously been described elsewhere (7),
were used. This group of patients included 47 patients with
EaSSc, 48 with nonfibrotic SSc, and 43 age- and sex-matched
healthy controls. In addition, 51 patients with limited cuta-
neous SSc (lcSSc) and 35 with diffuse cutaneous SSc (dcSSc)
were enrolled.
Each patient underwent a complete evaluation to
correctly allocate them to the different study groups, as pre-
viously described (7). The baseline clinical assessment was
performed between the end of 2011 and mid-2012, allowing
the follow-up data to be evaluated retrospectively for disease
progression. Data were available for 143 patients (34 with
EaSSc, 38 with nonfibrotic SSc, 41 with lcSSc, and 30 with
dcSSc). Progression was defined as follows: 1) for those
with dcSSc, death attributable to SSc, worsening of lung
function (i.e., a reduction in the FVC of ≥10% from base-
line or a reduction in the DLCO of ≥15% from baseline),
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identification of PAH, or identification of digital ulcers in
the absence of a history of digital ulceration; 2) for those
with lcSSc, the same criteria as applied to dcSSc, as well as
the progression of skin disease from limited to diffuse
involvement; 3) for those with nonfibrotic SSc, the same cri-
teria as applied to lcSSc, as well as the progression of skin
or lung involvement and identification of fibrotic features; 4)
for those with EaSSc, the same criteria as applied to nonfi-
brotic SSc, as well as the identification of telangiectasias or
puffy fingers.
The baseline demographic and clinical characteristics
of the patients in both the discovery cohort and the replica-
tion cohort are summarized in Tables 1 and 2. The study was
performed in accordance with the Declaration of Helsinki
and approved by the local ethics committee (Comitato Etico
Area B).
Serum multiplex assay. A total of 88 markers of
immune activation, inflammation, and tissue damage and addi-
tional markers of vascular remodeling and adhesion were
selected for the analysis (a full list of the tested markers is
available upon request from the corresponding author).
Peripheral blood was obtained by venipuncture from all sub-
jects at the time of enrollment. Serum was separated by cen-
trifugation at 1,500g for 10 minutes and stored at 80°C until
analyzed. Serum analyses were performed at the MultiPlex
Core Facility of the Laboratory of Translational Immunology
(University Medical Center Utrecht). An in house–developed
multiplex immunoassay based on Luminex technology (xMAP;
Luminex) was utilized, as previously described (14).
For statistical analysis, serum concentrations below
the detection limit were converted to one-half of the lower
limit of detection. When more than 5% of measurements
were below the detection limit (out of range >5%), the ana-
lyte was excluded from further analysis. After performing this
quality control step, 46 proteins passed the threshold to
undergo statistical analysis in the discovery cohort (a com-
plete list of the 42 molecules that did not meet this prerequi-
site is available upon request from the corresponding author).
Statistical analysis. Statistical analyses were con-
ducted using SPSS software (version 22.0; IBM). Continuous
variables are expressed as the mean  SD; data were log-
transformed before being analyzed. In the discovery phase,
one-way analysis of variance (ANOVA) was performed, along
with an ANOVA polynomial linear test for trend. In both
tests, the exploratory significance threshold was P = 0.1.
Table 1. Baseline demographic and clinical characteristics of the
patients in the discovery cohort*
EaSSc
(n = 21)
Nonfibrotic SSc
(n = 15)
Female, no. (%) 20 (95.2) 14 (93.3)
Age, mean  SD years 53  16 53  14
RP duration, mean  SD years 10  8 13  10
Disease duration, mean  SD years NA 8  6
Autoantibodies, no. (%)
ANA 18 (85.7) 15 (100)
Anti–RNAP III 0 (0) 0 (0)
ACA 14 (66.7) 11 (73.3)
Anti–topo I 2 (9.5) 2 (13.3)
NVC changes, no. (%) 17 (80.9) 14 (93.3)
Telangiectasias, no. (%) 0 (0) 4 (26.7)
Puffy fingers, no. (%) 0 (0) 13 (86.7)
Digital ulcers, no. (%) 0 (0) 2 (13.3)
* Patients were stratified according to disease subsets of early sys-
temic sclerosis (EaSSc) and nonfibrotic SSc (definite SSc, without
lung or skin fibrosis). RP = Raynaud’s phenomenon; NA = not appli-
cable; ANA = antinuclear antibody; anti–RNAP III = anti–RNA poly-
merase III antibody; ACA = anticentromere antibody; anti–topo I =
anti–topoisomerase I antibody; NVC = nailfold videocapillaroscopic.
Table 2. Baseline demographic and clinical characteristics of the patients in the replication cohort*
EaSSc (n = 47) Nonfibrotic SSc (n = 48) lcSSc (n = 51) dcSSc (n = 35)
Female, no. (%) 44 (93.6) 48 (100) 48 (94.1) 31 (88.6)
Age, mean  SD years 53  14 62  13 62  10 55  13
RP duration, mean  SD years 11  10 17  11 18  11 15  11
Disease duration, mean  SD years NA 9  8 14  8 12  10
Autoantibodies, no. (%)
None 6 (12.8) 1 (2.1) 3 (5.9) 1 (2.9)
ANA 41 (87.2) 47 (97.9) 48 (94.1) 34 (97.1)
Anti–RNAP III 3 (6.4) 0 (0) 3 (5.9) 3 (8.6)
ACA 22 (46.8) 42 (87.5) 22 (43.1) 1 (2.9)†
Anti–topo I 7 (14.9) 4 (8.3) 15 (29.4) 24 (68.6)†
NVC changes, no. (%) 42 (89.4) 48 (100) NA NA
Telangiectasias, no. (%) 0 (0) 29 (60.4) 34 (66.7) 30 (85.7)
Puffy fingers, no. (%) 0 (0) 40 (83.3) NA NA
Digital ulcers, no. (%) 0 (0) 3 (6.3) 12 (23.5) 7 (20)
Pitting scars, no. (%) 0 (0) 7 (14.6) 9 (17.6) 2 (5.7)
ILD, no. (%) 0 (0) 0 (0) 17 (33.3) 17 (48.6)
PAH, no. (%) 0 (0) 0 (0) 2 (4) 0 (0)
Use of immunosuppressants, no. (%) 0 (0) 1 (2.1) 7 (13.7) 12 (34.3)
* Patients were stratified according to disease subsets of early systemic sclerosis (EaSSc), nonfibrotic SSc (definite SSc,
without lung or skin fibrosis), limited cutaneous SSc (lcSSc), and diffuse cutaneous SSc (dcSSc). RP = Raynaud’s phe-
nomenon; NA = not applicable; ANA = antinuclear antibody; anti–RNAP III = anti–RNA polymerase III antibody; NVC
= nailfold videocapillaroscopic; ILD = interstitial lung disease; PAH = primary pulmonary arterial hypertension.
† One patient was double-positive for anticentromere antibodies (ACAs) and anti–topoisomerase I antibodies (anti–topo I).
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In the replication step, the mean concentrations of
the molecules selected in the discovery step were compared
using an ANOVA test and an ANOVA polynomial linear test
for trend. Results were declared significant at the level of P =
0.05, after adjustment for multiple comparisons according to
the Bonferroni method (i.e., 0.05/13 = 0.0038). When the glo-
bal ANOVA F score was significant at the adjusted threshold,
pairwise comparisons with the Tukey’s method were per-
formed, with significant differences defined at the P value
threshold of 0.05.
Table 3. Summary of findings in the discovery cohort*
Analyte
Cohort ANOVA P†
Healthy controls EaSSc Nonfibrotic SSc F-test
Polynomial test
for trend
IL-13, pg/ml 24.5  21.4 258.5  630.3 112.8  273.5 NS NS
IL-18, pg/ml 52.2  20.0 86.6  62.7 97.5  33.8 0.039‡ 0.012‡
G-CSF, ng/ml 0.439  0.837 325.0  1345.0 124.1  454.7 0.019‡ NS
MIF, pg/ml 759.1  631.5 916.9  550.9 690.7  429.4 NS NS
CCL2, pg/ml 74.3  29.0 96.2  29.4 101.8  39.7 0.076‡ 0.036‡
CCL4, pg/ml 93.6  59.2 129.5  64.0 138.0  55.6 0.051‡ 0.020‡
CCL5, ng/ml 166.5  49.5 142.1  40.9 118.8  58.8 0.033‡ 0.013‡
CCL11, pg/ml 45.7  25.6 118.3  140.1 65.2  31.4 0.041‡ NS
CCL17, pg/ml 210.8  97.1 247.2  123.3 264.9  222.3 NS NS
CCL18, ng/ml 565.7  219.1 745.3  647.3 896.6  668.9 NS NS
CCL19, pg/ml 28.3  20.0 82.6  86.3 182.2  404.6 0.033‡ 0.013‡
CCL22, pg/ml 494.7  114.2 467.9  185.7 505.9  268.7 NS NS
CCL25, pg/ml 729.2  439.3 581.1  311.2 562.1  260.9 NS NS
CXCL1, pg/ml 22.5  76.1 188.0  252.2 130.6  110.4 NS NS
CXCL5, pg/ml 549.3  383.7 478.4  294.3 462.6  400.5 NS NS
CXCL7, lg/ml 18.06  4.12 15.43  3.88 16.40  3.78 NS NS
CXCL9, pg/ml 76.6  23.4 144.7  93.5 93.7  45.3 0.027‡ NS
CXCL10, pg/ml 193.5  63.5 595.5  409.2 583.0  265.4 0.00005‡ 0.00004‡
CXCL11, pg/ml 32.2  24.7 61.8  54.5 64.8  49.9 NS 0.070‡
CXCL13, pg/ml 15.9  8.6 52.4  76.2 26.8  30.4 0.066‡ NS
Osteopontin, ng/ml 9.0  5.7 12.6  5.0 13.0  5.7 NS NS
MMP-1, ng/ml 14.90  7.12 16.86  12.05 19.53  16.72 NS NS
MMP-3, ng/ml 16.39  6.57 22.09  14.52 20.37  12.30 NS NS
MMP-8, ng/ml 39.71  18.56 51.80  35.46 51.18  28.10 NS NS
MMP-9, ng/ml 1,860.9  1,672.1 2,925.0  1,718.3 3,072.7  1,708.9 NS NS
Cathepsin A, pg/ml 791.2  347.0 1483.6  1334.4 1483.6  1334.4 NS NS
Cathepsin B, ng/ml 12.66  10.52 14.17  7.39 12.83  5.92 NS NS
Cathepsin L, pg/ml 2,905.6  360.5 2,884.0  346.6 3,381.1  992.0 0.051‡ 0.062‡
Cathepsin S, ng/ml 9.99  1.81 12.13  2.78 11.45  2.26 0.063‡ NS
TNFRII, pg/ml 1,041.6  413.7 1,940.9  912.1 1,660.1  632.5 0.001‡ 0.007‡
Galectin 1, ng/ml 19.68  4.94 25.58  6.40 28.38  17.45 NS NS
Galectin 3, ng/ml 43.12  6.26 43.33  8.18 38.27  6.58 0.094‡ 0.084‡
TIMP-1, ng/ml 225.1  28.6 247.6  38.3 253.5  62.7 NS NS
C5a, ng/ml 49.44  10.46 58.91  13.82 51.42  18.15 NS NS
S100A8, ng/ml 169.2  55.2 145.0  40.1 163.1  76.1 NS NS
CHI3L1, ng/ml 83.70  74.27 95.45  45.80 102.07  35.71 NS 0.084‡
P-selectin, ng/ml 362.7  226.4 448.9  306.8 328.5  140.1 NS NS
Endoglin, pg/ml 686.9  309.0 850.0  297.2 793.3  363.5 NS NS
Angiopoietin 1, ng/ml 46.87  10.13 45.40  19.12 51.05  18.74 NS NS
PAI-1, lg/ml 11.72  1.36 11.85  1.47 11.81  3.79 NS NS
Adiponectin, lg/ml 234.5  82.3 217.8  86.0 206.7  88.5 NS NS
Adipsin, pg/ml 2,228.2  173.0 2,171.9  261.4 2,051.4  342.4 NS NS
Leptin, pg/ml 5,965.4  3133.4 5,659.0  3824.4 4,645.3  952.2 NS NS
Chemerin, ng/ml 331.5  35.6 306.9  43.0 311.5  27.8 NS NS
Apelin, ng/ml 24.86  2.42 26.06  4.35 25.04  5.15 NS NS
Resistin, ng/ml 41.67  12.66 56.11  38.94 58.30  32.80 NS NS
* Values are the mean  SD. EaSSc = early systemic sclerosis; nonfibrotic SSc = definite SSc, without lung or skin fibrosis; IL-13 = interleukin-13;
G-CSF = granulocyte colony-stimulating factor; MIF = macrophage migration inhibitory factor; MMP-1 = matrix metalloproteinase 1; TNFRII =
tumor necrosis factor receptor type II; TIMP-1 = tissue inhibitor of metalloproteinases 1; CHI3L1 = chitinase 3–like protein 1; PAI-1 = plasmino-
gen activator inhibitor 1.
† P values were determined by one-way analysis of variance (ANOVA) F-test or by one-way ANOVA polynomial test for trend among all 3 groups.
Except where indicated otherwise, differences were not significant (NS).
‡ Significant difference at the P value threshold of <0.1.
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Heatmaps were used to visually explore the global
behavior of the biomolecules that were replicated. To this
end, data were normalized by scaling on an interval of 0–1.
Normalization of the data and visualization were performed
using Orange data mining software (15).
For analysis of evolution of the molecular concentra-
tions, Turnbull’s nonparametric estimator for interval-censored
data (16) was used, since the collection of data was uneven,
and statistical significance of the model was assessed using
generalized log rank test statistics (17) after 10,000-fold
exact permutation testing. Evolution of the concentration of
each biomolecule was evaluated for those molecules that
passed the replication step (as described above), choosing an
optimal cutoff point that was within the 10th and 90th
percentiles of the distribution of each molecule within each
disease subset.
Data from patients in each disease subset were
stacked to calculate the predicted survival and its associated
test statistic in the overall SSc population. Survival analyses
were performed using a custom Python code (written by LB;
available upon request from the corresponding author). Mat-
plotlib version 2.0.0 (18) was used to plot the survival
curves.
RESULTS
Increased levels of CXCL10, CXCL11, tumor
necrosis factor receptor type II (TNFRII), and chitinase
3–like protein 1 (CHI3L1) in EaSSc and nonfibrotic
SSc. Of the 88 circulating proteins studied in the serum
of subjects in the discovery cohort, comprising 36 SSc
patients and 11 healthy control counterparts, 16 proteins
were found to be altered in the patients at the explora-
tory P value threshold of 0.1. These 16 proteins were
interleukin-18 (IL-18), granulocyte colony-stimulating
factor (G-CSF), CCL2, CCL4, CCL5, CCL11, CCL19,
CXCL9, CXCL10, CXCL11, CXCL13, cathepsin L,
cathepsin S, TNFRII, galectin 3, and CHI3L1 (Table 3).
All 16 analytes that passed the exploratory threshold for
statistical significance in the discovery cohort were con-
sidered for replication analysis.
Quality testing was then independently performed
in the replication cohort after the serum samples were
assayed. In the replication cohort, the concentrations of
G-CSF, cathepsin L, and galectin 3 were below the detec-
tion limit in >5% of samples tested, and therefore all 3
were excluded from further experiments. Thus, only 13
analytes, as listed in Table 4, underwent statistical analy-
sis in the replication cohort, consisting of serum samples
from 43 healthy donors and 181 patients with SSc,
including the subsets of EaSSc, nonfibrotic SSc, lcSSc,
and dcSSc.
In the replication analysis, 4 analytes, namely,
CXCL10, CXCL11, TNFRII, and CHI3L1, were found
to be increased both in patients with EaSSc and in
patients with nonfibrotic SSc as compared to healthy
controls (Table 4 and Figure 1A). Noteworthy, the
levels of all 4 of these markers showed linearly increas-
ing trends toward significant differences from healthy
controls when compared to patients with EaSSc and to
patients with nonfibrotic SSc. Importantly, in addition
to their levels being increased in EaSSc and nonfibrotic
SSc, these molecules were also up-regulated in patients
with lcSSc and those with dcSSc (Figure 1B), suggesting
that increased levels of CXCL10, CXCL11, TNFRII,
and CHI3L1 in EaSSc and/or nonfibrotic SSc may mark
disease progression.
This hypothesis was further substantiated by
the fact that CXCL10, CXCL11, TNFRII, and
CHI3L1 displayed an overall progressive increase in
concentration when patients with EaSSc, patients with
nonfibrotic SSc, and patients with fibrotic SSc (lcSSc
and dcSSc considered as a whole group) were com-
pared to healthy controls (Figure 1C). Some of the
patients with lcSSc and those with dcSSc were receiv-
ing immunosuppressive medications at the time of
study inclusion (Table 2); nevertheless, we found no
difference in the concentrations of the replicated
molecules when stratifying patients according to
whether they were or were not receiving immunosup-
pressive therapy (data not shown). A large proportion
of the patient population was positive for anticen-
tromere antibodies (ACAs), but no association with
the levels of the candidate proteins and the pattern
of ACA expression could be detected (data not
shown).
Association of CXCL10 and TNFRII concentra-
tions with shortest disease progression times. Overall,
59 (41.2%) of 143 patients with available follow-up
data within the replication cohort showed disease pro-
gression after a maximum follow-up time of 59.6
months. Nonexclusive causes of progression included
death (n = 8), worsening of lung function (n = 38),
new onset of PAH (n = 4), worsening of skin disease
(n = 10), new onset of digital ulcers (n = 4), and iden-
tification of telangiectasias (n = 7). The estimated
median time to evolution of disease (from all causes)
was between 52.6 months and 52.9 months. Patients
with higher levels of CXCL10 and TNFRII showed a
shorter progression time from EaSSc and nonfibrotic
SSc to other disease subsets. In particular, the most
consistent results were observed in those with
increased CXCL10 levels, both in the EaSSc (P =
0.01) and nonfibrotic SSc (P = 0.006) subsets
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Figure 1. Replicated immune activation markers differently expressed in the circulation of patients with early systemic sclerosis (EaSSc), those
with definite SSc in the absence of fibrosis of the skin and internal organs (nonfibrotic SSc [nonfibSSc]), or those with definite SSc in the presence
of fibrosis of the skin and internal organs (limited cutaneous SSc [lcSSc] and diffuse cutaneous SSc [dcSSc]) compared to healthy controls (HC). A
and B, Concentrations of the soluble analytes that were replicated as being significantly differently expressed (CXCL10, CXCL11, tumor necrosis
factor receptor type II [TNFRII], and chitinase 3–like protein 1 [CHI3L1]) in comparisons of healthy controls to patients with EaSSc and those
with nonfibrotic SSc (A) or to patients with EaSSc, those with nonfibrotic SSc, those with lcSSc, and those with dcSSc (B) in the replication
cohort. Each symbol represents an individual patient; horizontal lines with bars show the mean and SD. Differences in the serum concentration
levels were considered significant at the Bonferroni-adjusted threshold of P < 0.0038 by one-way analysis of variance (ANOVA) polynomial test
for trend and/or one-way ANOVA test with Tukey’s post hoc test. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. C, Heatmaps
of analyte profiles in healthy controls and each SSc disease subset (patients with lcSSc and those with dcSSc considered jointly). Data were nor-
malized for each analyte individually, and a color profile was made to show the cytokine pattern of each individual (represented by colored hori-
zontal blocks: bright green = minimal expression; bright red = maximal expression).
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(Figure 2A). These results, together with the different
rates of progression observed in patients with dcSSc (P =
0.029), accounted for the overall different times of
evolution to worse disease subsets between the high-
expressing and low-expressing CXCL10 patient groups
in the overall SSc population (P = 0.009) (Figure 2A).
Similarly, categorization of TNFRII levels could
explain the different rates of disease progression in
patients with EaSSc (P = 0.009) (Figure 2B), in those
with nonfibrotic SSc (P = 0.0005) (Figure 2B), and in
those with lcSSc (P = 0.0065) (data not shown).
Furthermore, the concentrations of TNFRII were mar-
ginally associated with disease evolution times in the
overall SSc population (P = 0.044) (Figure 2B).
Higher levels of CHI3L1 were associated with
a shorter disease evolution time in patients with
dcSSc (P = 0.004) (data not shown). However, levels
of CHI3L1 were not associated with disease evolu-
tion times in patients in the early/nonfibrotic phase
of SSc or in patients with lcSSc. Finally, the concen-
trations of CXCL11 were not associated with time
to evolution in any of the disease subsets (data not
shown).
DISCUSSION
SSc is a heterogeneous disease and patients can
be clinically stratified into different clinical phenotypes.
Although SSc with overt fibrosis has traditionally been
the subject of extensive research, little is known about
the pathophysiologic alterations that might characterize
patients with preclinical features of scleroderma
(EaSSc) or patients with a formal diagnosis of SSc who
lack fibrotic features. Recent endeavors have clearly
demonstrated that most patients with EaSSc are bound
to progress toward definite SSc (11,19), and efforts
have been made to formalize the criteria for recogni-
tion of SSc even in the absence of the prototypical hall-
marks of fibrotic changes (6). Nonetheless, biomarkers
that could be used to characterize the earliest stages of
disease and its progression are still lacking. Thus,
herein we have described for the first time the
Figure 2. Survival curves of disease evolution times in patients with EaSSc, those with nonfibrotic SSc, and all SSc patients in relation to low serum
levels versus high serum levels of CXCL10 (A) and TNFRII (B). Survival estimates were determined using Turnbull’s method for interval-censored
data. Generalized log rank test statistic probabilities were calculated using 10,000-fold exact permutation testing. See Figure 1 for definitions.
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identification and validation of 4 circulating biomark-
ers, CXCL10, CXCL11, TNFRII, and CHI3L1, that
could enable the discrimination of EaSSc and nonfi-
brotic SSc subsets from healthy controls. Most impor-
tantly, the concentrations of CXCL10 and TNFRII also
could identify those patients who show faster progres-
sion to definite disease or to lcSSc or dcSSc.
In previous studies, attempts have been made to
categorize SSc based on the level of circulating inflam-
mation markers. Liu and colleagues, for instance, based
their composite score of plasma interferon (IFN)–in-
ducible chemokines on the combination of CXCL10
and CXCL11, and described correlation of their levels
with the IFN signature and with the severity of lung,
muscle, and skin involvement in patients with fibrotic
SSc (20). We have recently shown that patients with
SSc without fibrotic features have the highest average
IFN signature score and the highest prevalence of the
IFN signature among the different disease subgroups
(EaSSc, lcSSc, and dcSSc) when compared to healthy
controls, with the EaSSc group closely following the
nonfibrotic SSc group and surpassing patients with
lcSSc and those with dcSSc in terms of the IFN score
and prevalence (8). Consistent with these findings, we
demonstrated herein that increased levels of CXCL10
and CXCL11 are present in the serum of patients with
nonfibrotic SSc and, to a smaller extent, in the serum
of patients with EaSSc. We herein also confirmed their
increased levels in the circulation of patients with lcSSc
and those with dcSSc, as has also been described previ-
ously (20,21), to levels similar to those observed in the
nonfibrotic SSc group.
The antiangiogenic effects of CXCL10 (22), as
well as its promoting role in the proliferation of vascu-
lar smooth muscle cells (23), support the notion of an
early role of CXCL10 in amplifying endothelial damage
and driving EaSSc and nonfibrotic SSc toward fibrotic
modifications. This notion is corroborated by the find-
ings observed in patients with localized scleroderma, in
whom circulating CXCL10 levels are also increased,
and whose increased levels correlate with disease activ-
ity (24). In this regard, the administration of anifrol-
umab, a monoclonal antibody directed against the
IFNa receptor type 1, in patients with fibrotic SSc was
found to be associated with a decrease in the blood
and skin IFN signature (25) and with a drop in circulat-
ing CXCL10 levels as well (26); the down-regulation of
the IFN signature correlated with the decrease in the
levels of CXCL10. It is intriguing to speculate how the
administration of anifrolumab would affect the rate of
progression of EaSSc and nonfibrotic SSc, in particular
in terms of halting the development of fibrotic features
in those individuals with the highest CXCL10 levels,
indicative of faster progression.
CXCL10 and CXCL11, as well as CXCL9—which
also showed a trend toward increased levels in patients
with nonfibrotic SSc in our cohort, but without reaching
a statistically significant difference from healthy controls
—all bind to CXCR3 on activated lymphocytes (T cells,
natural killer [NK] cells, and NK T [NKT]–like cells) and
endothelial cells (ECs). In spite of a well-documented
increased expression of CXCL10 and CXCL9 in the
serum and in the lesional skin of SSc patients, the expres-
sion of CXCR3 has been shown to be reduced in SSc
skin and to be confined to ECs only (27). CXCR3-defi-
cient mice challenged with bleomycin displayed a higher
incidence of mortality attributable to increased lung
fibrosis when compared to wild-type mice. A possible rea-
son for this phenomenon is the decreased recruitment of
NK and NKT-like cells in the lung and the consequent
decline in levels of antifibrotic IFNc in the tissue (28).
The decrease in CXCR3 levels in patients with
SSc could reflect a mechanism of down-regulation upon
overexposure to its ligands and to proinflammatory
mediators and/or mirror the progressive decrease in
leukocyte infiltration in late stages of fibrosis. In this
regard, it would be of interest to investigate the expres-
sion of CXCR3 in patients with EaSSc and those with
nonfibrotic SSc in whom fibrosis has not yet developed,
and to follow up the pattern of expression over time in
parallel with the progression of disease and lung
involvement. These investigations would be particularly
relevant in those individuals with higher circulating
levels of CXCL10, who showed faster rates of disease
progression in our cohort.
Circulating TNFRII has recently been described
as a biomarker of disease activity in juvenile dermato-
myositis (29), while in rheumatoid arthritis, not only is
TNFRII typically associated with disease activity, but
also its levels have been found to be increased in the
circulation years before disease onset (30). Similarly,
we found that the levels of TNFRII were increased in
patients with preclinical EaSSc, and increased to a
greater extent in those in whom SSc developed faster.
In patients with nonfibrotic SSc, the observed increase
in TNFRII was even higher than that in patients with
EaSSc, and patients with the highest circulating con-
centrations had faster times of progression to fibrotic
disease. It is indeed of interest to observe that TNFRII
levels peaked in patients with lcSSc and those with
dcSSc. H€ugle et al also described an increase in
TNFRII levels in the circulation of patients with fibro-
tic SSc, which marked the activation of the T cell com-
partment (31). In the same study, TNFRII was also
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found to be overexpressed on T cells of the dermis of
patients, and positively correlated with the extent of
skin thickening. Furthermore, triggering of TNFRII on
T cells in vitro led to the release of profibrotic cytoki-
nes, which further stimulated collagen production by
fibroblasts (31). The shedding of soluble TNFRs
reflects a status of broad immune activation and, in the
case of TNFRII, predominantly mirrors the activation
of T cells (32). Taken together, these data suggest that
T cells might be implicated in the evolution process
in SSc. Nevertheless, the biologic implications of
increased TNFRII concentrations in the circulation of
SSc patients need to be clarified in future studies, since
the soluble receptor could either compete for TNFa
binding with T cells—thereby inhibiting its effects—or
act as a carrier of TNFa to different tissues and thus
stabilize the TNFa serum concentration—thereby func-
tioning as a reservoir.
A novel biomarker identified by our study is
CHI3L1, a proinflammatory cytokine proposed as a
biomarker of disease progression and severe prognosis
in several chronic inflammatory diseases and cancer
(33). Secreted by neutrophils, macrophages, vascular
smooth muscle cells, synovial cells, chondrocytes from
arthritic joints, hepatic stellate cells, and cancer cells,
CHI3L1 binds to collagen and glycosaminoglycans in
the extracellular matrix (34) and stimulates fibroblast
growth, thus participating in tissue remodeling and the
development of fibrosis. In SSc, its increased levels
in the circulation has been associated with articular
involvement and augmented levels of soluble IL-2
receptor a (35), a sign of T cell activation. CHI3L1 has
also been linked to lung fibrosis and reduction in the
DLCO, with documented protein expression in macro-
phages and neutrophils in lung biopsy specimens from
an SSc patient with lung inflammation and fibrosis
(36). Its gradual increase in levels occurring linearly
from healthy controls to patients with EaSSc to
patients with nonfibrotic SSc to the highest levels in
the lcSSc and dcSSc subsets, and its association with
shortest time of disease progression in patients with
dcSSc, could be a reflection of the different stages of
disease severity. These findings offer grounds to study
these molecules as prognostic biomarkers in SSc.
To our knowledge, this is the first study in a
large cohort of patients with EaSSc and patients with
nonfibrotic SSc conducted for validation of the
biomarkers generated before the development of overt
fibrosis. A limitation of our study is the fact that the
serum proteins were not measured longitudinally and
that the clinical data were collected retrospectively, and
as a consequence, follow-up data were not available for
each individual. In particular, it would have been of
interest to assess how the levels of the validated mole-
cules would be stratified after clinical progression. This
second measurement, however, would have created
problems with interpretation of the results, considering
the high intermeasurement variability of the multiplex
assays. Nevertheless, the results presented corroborate
the concept of nonfibrotic SSc as a separate, intermedi-
ate entity linking the preclinical stage of SSc to the
fibrotic, most severe subsets of the disease. We also for
the first time provide evidence of molecules whose up-
regulation in the serum is associated with faster pro-
gression to definite disease in patients with EaSSc or
faster development of fibrotic features in patients with
nonfibrotic SSc. The present study thus offers new
ground to understand the pathophysiologic mechanisms
of SSc progression and opens new avenues for disease
interception.
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